Description
Cipoxir-TZ — Dual-Action Therapy for Gastrointestinal and Mixed Bacterial Infections
Cipoxir-TZ combines Ciprofloxacin 500 mg with Tinidazole 600 mg, pairing a broad-spectrum fluoroquinolone that inhibits bacterial DNA replication with an agent highly effective against anaerobic bacteria and protozoal organisms. This dual mechanism gives physicians comprehensive coverage against the mixed bacterial and protozoal pathogens commonly responsible for infectious diarrhea, making single-agent therapy less effective on its own. Cipoxir-TZ addresses acute infectious diarrhea, amoebiasis, giardiasis, mixed bacterial and protozoal gastrointestinal infections and dysentery, giving franchise partners a genuinely comprehensive gastro-intestinal antimicrobial for physicians managing complex or mixed-infection presentations.
Combination Reliability Backed by Certified Manufacturing
Lxir Medilabs is an ISO and WHO-GMP certified pharmaceutical company headquartered in Panchkula, Haryana with manufacturing carried out at our Baddi, Himachal Pradesh facility. Combining a fluoroquinolone antibiotic with an antiprotozoal agent in one tablet requires precise formulation to keep both actives stable and bioavailable and Cipoxir-TZ is manufactured under strict quality control to maintain this consistency across every batch. For a PCD pharma franchise company in India, offering a well-formulated dual-therapy combination gives field partners a strong product to introduce to gastroenterologists and general physicians treating infectious diarrhea and mixed gut infections.
Product Highlights for Franchise Partners
- Composition: Ciprofloxacin HCl 500 mg + Tinidazole 600 mg
- Dosage Form: Tablets
- Pack Size: 10×10 Tablets
- Indications: Acute infectious diarrhea, amoebiasis, giardiasis, mixed bacterial and protozoal gastrointestinal infections, dysentery
- Key Benefit: Comprehensive antibacterial and antiprotozoal therapy for faster recovery and gastrointestinal health
- Suited For: Distributors and medical representatives expanding their gastro-intestinal and anti-infective range
Franchise partners looking to add a dual-action antibacterial and antiprotozoal combination to their portfolio can explore this and other formulations through our PCD pharma franchise division, with complete launch support.
Disclaimer: This is a prescription antibiotic and should be used strictly under the supervision of a registered medical practitioner.
